UF Ventures

Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases

Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).

IPOs Could Be Headed for a Rocky Road in 2023

Initial public offerings appear likely to remain sluggish for at least several months to start 2023, while special purpose acquisition companies, which provide businesses with alternative paths to public listings, face headwinds of their own. Hear what University of Florida professor Jay Ritter, has to say about a possible IPO drought.